Title: Effects of Bevacizumab and Recombinant Human Endostatin on Human Breast Cancer MCF-7 Xenografts in Nude Mice
Abstract: [Purpose] To investigate the effects of bevacizumab and recombinant human endostatin(rhES) on the tumor growth of human breast cancer MCF-7 xenografts in nude mice. [Methods] Human breast cancer xenografts were established from MCF-7 cells,and nude mice were randomly divided into control group,low-dose bevacizumab group,high-dose bevacizumab group,low-dose rhES group,high-dose rhES group,low-dose combination group and high-dose combination group. The body weight of nude mice,tumor volume and tumor weight were measured. The tumor inhibition rate was evaluated. [Results] Tumor weight was significantly decreased in low-dose bevacizumab group, high-dose bevacizumab group,low-dose combination group and high-dose combination group as compared with control(P0.01). The tumor growth inhibition rates in low-dose bevacizumab group,highdose bevacizumab group,low-dose combination group and high-dose combination group were 67.69%,68.88%,78.32% and 79.26%,respectively. Significant difference in tumor weight between low-dose combination group and low-dose bevacizumab group was observed(P0.05). There was no significant difference of tumor growth between rhES group and control group(P0.05). [Conclusion] Bevacizumab has an inhibitory effect on tumor growth of human breast cancer MCF-7 xenografts,and lowdose bevacizumab combined with rhES may enhance the antitumor activity.
Publication Year: 2014
Publication Date: 2014-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot